All In Biotech

Drug Trial Radar · NCT05703971

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

May 9, 2024

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Genprex, Inc.Industry
Sponsor type
Industry
First posted
Jan 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).

Conditions

  • Small Cell Lung Cancer Extensive Stage

Interventions

  • quaratusugene ozeplasmidBiological

    Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.

  • atezolizumabBiological

    Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1Time frame: First 21-days at each dose level
  2. Progression-Free Survival Rate (PFSR) - Phase 2Time frame: 18-weeks from Day 1 of maintenance therapy

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers, LLP

    Lone Tree, Colorado · Recruiting

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Recruiting

  • Oncology_Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio · Recruiting

  • Oncology_Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio · Recruiting

  • Oncology_Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio · Recruiting

  • Oncology_Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio · Recruiting

  • Oncology_Hematology Care Clinical Trials, LLC

    Fairfield, Ohio · Recruiting

  • Willamette Valley Cancer Institute (Oregon)

    Eugene, Oregon · Recruiting

  • Northwest Cancer Specialists, P.C.

    Portland, Oregon · Recruiting

  • Providence Cancer Institute

    Portland, Oregon · Recruiting

  • Northwest Cancer Specialists, P.C.

    Portland, Oregon · Recruiting

  • Northwest Cancer Specialists, P.C.

    Tigard, Oregon · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Northwest Cancer Specialists, P.C.

    Vancouver, Washington · Terminated

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.